Ahn-Gook Pharmaceutical Co., Ltd. (001540.XKRX) Dividend Analysis
Does Ahn-Gook Pharmaceutical Co. (001540.XKRX) pay a dividend?
Yes. Ahn-Gook Pharmaceutical Co. (001540.XKRX) pays a dividend: KRW 440.00 per share over the last twelve months, a dividend yield of 4.43% at the latest close.
It has raised its dividend per share for 1 year in a row, growing at 14.9% a year over the last 5 years. The payout takes about 23.0% of earnings.
Computed from company filings. Ex-dividend and payment dates are not part of those filings, so they are not shown here. This is analysis, not investment advice.
| Fiscal year | Per share | Change |
|---|---|---|
| 2025 | KRW 440.00 | +100.0% |
| 2024 | KRW 220.00 | 0.0% |
| 2023 | KRW 220.00 | 0.0% |
| 2022 | KRW 220.00 | 0.0% |
| 2021 | KRW 220.00 | 0.0% |
| 2020 | KRW 220.00 | 0.0% |
| 2019 | KRW 220.00 | 0.0% |
| 2018 | KRW 220.00 | 0.0% |
| 2017 | KRW 220.00 | 0.0% |
| 2016 | KRW 220.00 | 0.0% |
Newest 10 of 11 fiscal years; the chart below has the full series. Each payment counts toward the fiscal year it is paid for, so a final dividend paid in spring belongs to the year before. Figures are adjusted for stock splits, so a fall is a cut.
Dividend appears well-covered by both earnings and free cash flow, no sustained growth pattern yet.
Based on TTM and annual data · Not a buy/sell signal
Score Breakdown
Safety
40% of composite
Growth
35% of composite
Income
25% of composite
Composite = Safety (100) × 0.40 + Growth (60) × 0.35 + Income (100) × 0.25 = 86
Dividend Yield
4.43%
Per Share (TTM)
KRW 440.00
Payout Ratio
23.0%
5Y CAGR
14.9%
Dividend Safety
Earnings Payout
23.0%
FCF Payout
19.5%
FCF Coverage
5.1x
Dividend Growth
Per Share (TTM)
KRW 440.00
Growth Streak
1 year
5Y CAGR
14.9%
Dividend Income
Annual DPS (TTM)
KRW 440.00
Annual Income / KRW 10K
KRW 443
Payment frequency, ex-dividend and payment dates are not available from company filings. Check your broker or the company's investor relations page for the schedule.
Yield History
Ahn-Gook Pharmaceutical Co. (001540.XKRX) dividend: yield, safety and growth
Frequently asked
Does Ahn-Gook Pharmaceutical Co. (001540.XKRX) pay a dividend, and how much?+
Yes, Ahn-Gook Pharmaceutical Co. pays a regular dividend of about KRW 440.00 per share per year (a yield of roughly 4.4%). That is a payout ratio of about 23.0% of earnings, so it is comfortably covered by free cash flow. A low headline yield is not the same as a weak dividend: what matters is how well earnings and cash flow cover the payout, not the percentage alone. The full payout history and per-share figures are on this dividends tab.
Is Ahn-Gook Pharmaceutical Co.'s dividend safe?+
Ahn-Gook Pharmaceutical Co.'s dividend looks comfortably covered by free cash flow, with free cash flow covering the payout about 5.1 times over. Intrinsiqq scores its dividend safety at 100 out of 100, weighing the payout ratio, free-cash-flow coverage and balance-sheet strength. Safety matters more than yield: a payout you can rely on beats a high one you cannot.
Has Ahn-Gook Pharmaceutical Co. grown its dividend?+
Ahn-Gook Pharmaceutical Co. has raised its dividend for about 1 year in a row. Over the past five years the dividend has grown at roughly 14.9% a year. Consistent growth is one of the strongest signals of a durable, shareholder-friendly business, so read the streak alongside coverage on this tab.
What is Ahn-Gook Pharmaceutical Co.'s dividend payout ratio?+
Ahn-Gook Pharmaceutical Co. pays out about 23.0% of its earnings as dividends. A lower payout ratio leaves more room to keep raising the dividend and to absorb a bad year, while a very high ratio can signal a payout under pressure. On this measure the dividend is comfortably covered by free cash flow. See the dividend-safety breakdown for the free-cash-flow view, which is often more telling than earnings.
Related stocks: Drug Manufacturers - Specialty & Generic
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.